Compare JAGX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | XAIR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.4M |
| IPO Year | 2014 | 2015 |
| Metric | JAGX | XAIR |
|---|---|---|
| Price | $0.32 | $0.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $10.00 |
| AVG Volume (30 Days) | ★ 476.7K | 343.5K |
| Earning Date | 04-07-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | 62.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | $3,705,000.00 |
| Revenue This Year | $61.58 | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.31 | $0.15 |
| 52 Week High | $13.25 | $3.78 |
| Indicator | JAGX | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 33.95 |
| Support Level | N/A | $0.43 |
| Resistance Level | $0.46 | $0.82 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.58 | 15.35 |
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.